We are live on
!
Find out more
LPC
Lion Point Capital Portfolio holdings
AUM
$16.7M
1-Year Est. Return
119.35%
This Fund
S&P 500
This Quarter
Est. Return
-4.4%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$224M
AUM Growth
+$3.13M
(+1.4%)
Cap. Flow
+$13.8M
Cap. Flow
% of AUM
6.13%
Top 10 Holdings %
Top 10 Hldgs %
93.45%
Holding
37
New
6
Increased
4
Reduced
4
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$1.1M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$1.07M |
| 3 |
Humacyte
HUMA
|
+$778K |
| 4 |
Replimune Group
REPL
|
+$687K |
| 5 |
Insmed
INSM
|
+$457K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chord Energy
CHRD
|
+$15.7M |
| 2 |
Ardelyx
ARDX
|
+$1.37M |
| 3 |
TSVT
2seventy bio
TSVT
|
+$1.13M |
| 4 |
MRNS
Marinus Pharmaceuticals, Inc
MRNS
|
+$933K |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$761K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.16% |
| 2 | Healthcare | 10.07% |
| 3 | Consumer Discretionary | 1.42% |
| 4 | Energy | 1.05% |
| 5 | Communication Services | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LUMO
26
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $300K | 0.13% |
90,794
+12,443
| +16% | +$38.8K |
|
|
BFIIW
27
CALL
DELISTED
BurgerFi International, Inc. Warrant
BFIIW
| $235K | 0.1% |
2,083,438
| – | – |
|
28
Microsoft
MSFT
$3.45T
| $31.6K | 0.01% |
100
| – | – |
|
29
Alphabet (Google) Class C
GOOG
$4.36T
| $13.2K | 0.01% |
100
| – | – |
|
30
Chevron
CVX
$392B
| $7.76K | ﹤0.01% |
+46
| New | +$7.43K |
|
|
31
Chord Energy
CHRD
$7.9B
| – | – |
-102,403
| Closed | -$15.7M |
|
|
MRSN
32
CALL
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-5,840
| Closed | -$480K |
|
|
ORGN
33
DELISTED
Origin Materials
ORGN
| – | – |
-3,333
| Closed | -$426K |
|
|
TSVT
34
DELISTED
2seventy bio
TSVT
| – | – |
-111,667
| Closed | -$1.13M |
|
|
PDCE
35
DELISTED
PDC Energy, Inc.
PDCE
| – | – |
-100
| Closed | -$7.11K |
|
|
HZNP
36
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-7,400
| Closed | -$761K |
|
Similar funds
PA
SR
SCTC
SRA
CP
B
BCPE
AE
Lion Point Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Lion Point Capital held 37 positions worth $224M, up 1.4% from $221M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Lion Point Capital deployed $13.8M of net new capital in Q3 2023, opening 6 new positions and adding to 4 existing holdings. Its largest new stake was Travere Therapeutics: 78,000 shares worth $697K.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Ardelyx, an estimated $1.37M trimmed.
- Lion Point Capital's largest Q3 2023 buy was Travere Therapeutics: 78,000 shares worth $697K.
- Lion Point Capital added most to Insmed in Q3 2023, an estimated $457K increase.
- Lion Point Capital's biggest Q3 2023 reduction was Ardelyx, cutting an estimated $1.37M.
- Lion Point Capital fully exited Chord Energy in Q3 2023, selling an estimated $15.7M.
- Lion Point Capital's ten largest holdings make up 93% of its $224M portfolio in Q3 2023.
- Lion Point Capital opened 6 new positions and closed 6 in Q3 2023.
- Lion Point Capital's portfolio value rose 1.4% quarter-over-quarter to $224M.
Based on Lion Point Capital's 13F filing for Q3 2023, filed 14 Nov 2023.